Literature DB >> 18310257

Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis.

Robson A S Santos1, Anderson J Ferreira, Ana Cristina Simões E Silva.   

Abstract

In the past few years, the classical concept of the renin-angiotensin system (RAS) has experienced substantial conceptual changes. The identification of: the renin/prorenin receptor; the angiotensin-converting enzyme homologue, ACE2, as an angiotensin peptide-processing enzyme and a virus receptor for severe acute respiratory syndrome, the Mas as a receptor for angiotensin (1-7) [Ang(1-7)], and the possibility of signaling through ACE have contributed to switch our understanding of the RAS from the classical limited-proteolysis linear cascade to a cascade with multiple mediators, multiple receptors and multifunctional enzymes. With regard to Ang(1-7), the identification of ACE2 and of Mas as a receptor implicated in its actions contributed to decisively establish this heptapeptide as a biologically active member of the RAS cascade. In this review, we will focus on the recent findings related to the ACE2-Ang(1-7)-Mas axis and, in particular, on its putative role as an ACE-Ang II-AT(1) receptor counter-regulatory axis within the RAS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310257     DOI: 10.1113/expphysiol.2008.042002

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  155 in total

Review 1.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

2.  Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide.

Authors:  Tanya M Gwathmey; Brian M Westwood; Nancy T Pirro; Lijun Tang; James C Rose; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

3.  Reduced systolic pressure load decreases cell-cycle activity in the fetal sheep heart.

Authors:  P F O'Tierney; D F Anderson; J J Faber; S Louey; K L Thornburg; G D Giraud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-19       Impact factor: 3.619

4.  Determination of Angiotensin-(1-7) with HPLC/Fluorescence-Detection.

Authors:  Miriam Russ; Susanne Hauser; Reinhold Wintersteiger; Joachim Greilberger; Michaela Andrä; Astrid Ortner
Journal:  J Fluoresc       Date:  2015-10-09       Impact factor: 2.217

Review 5.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

6.  Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.

Authors:  Thomas Simon O'Hagan; Whitney Wharton; Patrick Gavin Kehoe
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 7.  The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure.

Authors:  John Kuchtey; Rachel W Kuchtey
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-12       Impact factor: 2.671

Review 8.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

9.  Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke.

Authors:  Robert W Regenhardt; Fiona Desland; Adam P Mecca; David J Pioquinto; Aqeela Afzal; J Mocco; Colin Sumners
Journal:  Neuropharmacology       Date:  2013-04-11       Impact factor: 5.250

Review 10.  Neuroimmune communication in hypertension and obesity: a new therapeutic angle?

Authors:  Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.